Report ( C - project coordinator, P - principal investigator, T - team contributor ) |
Link |
Role |
Daratumumab combination therapy for newly-diagnosed multiple myeloma (2020) |
|
C |
Avapritinib for gastrointestinal stromal tumours (2020) |
|
C |
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (2019-2020) |
|
C |
Dupilumab for treating severe asthma (2019) |
|
T |
Ustekinumab for treating moderately to severely active ulcerative colitis (2019) |
|
C |
Cemiplimab for treating squamous cell carcinoma (2018-2019) |
|
C, P |
Cabozantinib for untreated locally advanced or metastatic renal cell carcinoma (2018) |
|
T |
Tofacitinib for moderately to severely active ulcerative colitis (2018) |
|
T |
Daratumumab in combination with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (2018) |
|
T |
Ocrelizumab for treating relapsing multiple sclerosis (2018) |
|
C |
Atezolizumab after platinum chemotherapy, for treating urothelial, metastatic bladder cancer (2017) |
|
C, P |
Afamelanotide for treating erythropoietic protoporphyria (2017) |
|
T |
Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids (2016) |
|
C |
Migalastat for treating Fabry disease (2016) |
|
C, P |
Sofosbuvir for treating chronic hepatitis C (2016) |
|
C, P |
Cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma (2016) |
|
T |
Necitumumab for untreated advanced, metastatic, squamous non-small-cell lung cancer (2016) |
|
T |
Nivolumab for treating advanced, untreated, unresectble, melanoma (2015) |
|
T |
Simeprevir for treating genotype 1 or 4 chronic heptitis (2014) |
|
T |
Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer (2012) |
|
T |
Aripiprazole for the treatment of schizophrenia in adolescents (aged 15-17 years) (2010) |
|
T |
Vinflunine for the second line treatment of transitional cell carcinoma of the urothelial tract |
|
T |
Entecavir for the treatment of chronic hepatitis B (2008) |
|
T |